Mixed connective tissue disease medical therapy

Revision as of 14:56, 7 May 2018 by Shamila Habibi (talk | contribs) (→‎Medical Therapy)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mixed connective tissue disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mixed connective tissue disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mixed connective tissue disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mixed connective tissue disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Mixed connective tissue disease medical therapy

on Mixed connective tissue disease medical therapy

Mixed connective tissue disease medical therapy in the news

Blogs onMixed connective tissue disease medical therapy

Directions to Hospitals Treating Mixed connective tissue disease

Risk calculators and risk factors for Mixed connective tissue disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

The treatment of patients with MCTD depends on type of internal organ involvement, phase of the disease, and rate of disease progression. Treatment strategies must follow conventional treatments that are used for similar problems in other rheumatic diseases (SLE, scleroderma, polymyositis). Usually the treatment of patients with MCTD include low doses of steroids, NSAIDs, immunosuppressive drugs, and biologic agents. The treatment options in refractory cases or in severe clinical conditions include immunoglobulins, cytotoxic agents, and biologic drugs.

Medical Therapy

References

  1. 1.0 1.1 Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.
  2. Kim P, Grossman JM (August 2005). "Treatment of mixed connective tissue disease". Rheum. Dis. Clin. North Am. 31 (3): 549–65, viii. doi:10.1016/j.rdc.2005.04.008. PMID 16084325.
  3. Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.

Template:WH Template:WS